Suomi - suomi - Fimea (Suomen lääkevirasto)

pharmacia - cyclophosphamidum monohydricum - injektiokuiva-aine - syklofosfamidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

pharmacia - cyclophosphamidum - tabletti - 50 mg - syklofosfamidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - cyclophosphamidum monohydricum - injektiokuiva-aine, liuosta varten - syklofosfamidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - cyclophosphamidum monohydricum - tabletti, päällystetty - 50 mg - syklofosfamidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

paranova oy - cyclophosphamidum monohydricum - injektiokuiva-aine, liuosta varten - syklofosfamidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

baxter oy - cyclophosphamide monohydrate - injektiokuiva-aine, liuosta varten - syklofosfamidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

baxter oy - cyclophosphamide monohydrate - tabletti, päällystetty - 50 mg - syklofosfamidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

orifarm oy - cyclophosphamide monohydrate - injektiokuiva-aine, liuosta varten - syklofosfamidi

Euroopan unioni - suomi - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - multiple myeloma - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. yhdessä bortetsomibin kanssa, talidomidin ja deksametasonin hoitoon aikuispotilailla, joilla on äskettäin diagnosoitu multippeli myelooma, jotka ovat oikeutettuja autologisen kantasolujen siirto. yhdessä lenalidomidin ja deksametasonin tai bortetsomibi ja deksametasoni, hoitoon aikuisille potilaille, joilla on multippeli myelooma, jotka ovat saaneet vähintään yhtä aiempaa hoitoa. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. monoterapiana aikuispotilaille, joilla oli uusiutunut ja refraktorinen multippeli myelooma, joiden aiempi hoito, mukana proteasomin estäjä ja immunomoduloivan aineen, ja jotka ovat osoittaneet taudin etenemistä viimeinen hoito. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sandoz gmbh - rituksimabi - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastiset aineet - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. on vain vähän tietoa turvallisuudesta ja tehosta potilailla, joita on aiemmin hoidettu monoklonaalisia vasta-aineita, mukaan lukien rituksimabi tai potilaat eivät sietäneet aiemman rituksimabi plus kemoterapiaa. ks. kohta 5. 1 lisätietoja. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimabi on todettu hidastavan etenemistä nivelvaurioita mitattuna x-ray ja parantaa fyysistä toimintakykyä, kun sitä annetaan yhdessä metotreksaatin kanssa. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).